Menú

Inicio Revista Formación Noticias Agenda Categorías Revista y sociedades

Plasmapheresis: its use in multiple sclerosis and other demyelinating processes of the central nervous system. An observation study

J.E. Meca-Lallana, H. Rodríguez-Hilario, S. Martínez-Vidal, I. Saura-Luján, A. Carretón-Ballester, J.B. Escribano-Soriano, J.J. Martín-Fernández, A. Genovés-Aleixandre, E. Mateo-Bosch, A. Fernández-Barreiro Journal 37(10) ● Publication date 16/11/2003 ● Original ● Views 14948 ● Downloads 1361 Castellano English Português

Download PDF
ESP Add citation to
your library

Share this article on social networks:

Search in PubMed

By author

Meca-Lallana JE Rodriguez-Hilario H Martinez-Vidal S Saura-Lujan I Carreton-Ballester A Escribano-Soriano JB Martin-Fernandez JJ Genoves-Aleixandre A Mateo-Bosch E Fernandez-Barreiro A

By keyword

Demyelinization Multiple sclerosis Plasmapheresis Progression Severe relapses Treatment

See in PubMed

Current article Related articles

Vea nuestros másteres

[REV NEUROL 2003;37:917-926] PMID: 14634919 DOI: https://doi.org/10.33588/rn.3710.2003369

INTRODUCTION. We present a retrospective observation study aimed at analyzing the value of plasmapheresis in the management of patients with multiple sclerosis (MS) and other acute demyelinating processes affecting the central nervous system (CNS) who show severe exacerbations that do not respond well to conventional therapy with corticoids.

PATIENTS AND METHODS. A total of 11 patients were included in the study: nine with MS, one disseminated acute encephalomyelitis and one case of transverse myelitis. All of them presented an acute or subacute neurological deficit, which prevented them from carrying out their day-to-day activities, with or without repercussions on the EDSS, and with the risk of suffering a severe residual disability after not responding to intravenous methylprednisolone pulses. Each patient was submitted to three exchanges per week, for 2 weeks, with association of orally-administered prednisone and they were then evaluated after the last session and at one, six and twelve months.

RESULTS. Following plasmapheresis all the patients experienced a significant drop in disability and seven of them (77.7% of the total number with MS) even improved during the first month with respect to their basal situation (‘an extension of the Lazarus effect’). After a year’s follow-up, 100% of the patients still maintained the basal situation that was recovered from before exacerbation, and only two relapses were recorded. The patients with MS presented a ‘transient exacerbation’ after the second exchange. New therapy with immunosuppressants, immunomodulators or both was associated in eight cases.

CONCLUSIONS. We consider plasmapheresis to be a safe, effective therapeutic procedure in the management of patients with MS and other demyelinating processes affecting the CNS. Its use should be considered as first choice in severe relapses and in swiftly progressing forms that do not respond to intravenous methylprednisolone.

Keywords Demyelinization Multiple sclerosis Plasmapheresis Progression Severe relapses Treatment Classified in Esclerosis múltiple

Search in PubMed

By author

Meca-Lallana JE Rodriguez-Hilario H Martinez-Vidal S Saura-Lujan I Carreton-Ballester A Escribano-Soriano JB Martin-Fernandez JJ Genoves-Aleixandre A Mateo-Bosch E Fernandez-Barreiro A

By keyword

Demyelinization Multiple sclerosis Plasmapheresis Progression Severe relapses Treatment

See in PubMed

Current article Related articles

Search in PubMed

By author

Meca-Lallana JE Rodriguez-Hilario H Martinez-Vidal S Saura-Lujan I Carreton-Ballester A Escribano-Soriano JB Martin-Fernandez JJ Genoves-Aleixandre A Mateo-Bosch E Fernandez-Barreiro A

By keyword

Demyelinization Multiple sclerosis Plasmapheresis Progression Severe relapses Treatment

See in PubMed

Current article Related articles

Plasmapheresis: its use in multiple sclerosis and other demyelinating processes of the central nervous system. An observation study

Share this article on social networks:

Search in PubMed

By author

By keyword

See in PubMed

Abierta la Preinscripción

Máster en Neuropsicología de las Altas Capacidades Intelectuales

7ª Edición

Abierta la Preinscripción

Máster en Trastornos del Espectro Autista

12ª Edición

Search in PubMed

By author

By keyword

See in PubMed

Search in PubMed

By author

By keyword

See in PubMed